

Angela Nebbioso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/178979/publications.pdf>

Version: 2024-02-01

116
papers

6,475
citations

61984

43
h-index

71685

76
g-index

118
all docs

118
docs citations

118
times ranked

10250
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. <i>Nature Medicine</i> , 2005, 11, 77-84.	30.7	567
2	Cancer epigenetics: Moving forward. <i>PLoS Genetics</i> , 2018, 14, e1007362.	3.5	364
3	PML-RAR α /RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. <i>Cancer Cell</i> , 2010, 17, 173-185.	16.8	276
4	Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. <i>Oncogene</i> , 2009, 28, 781-791.	5.9	244
5	Trials with "epigenetic"™ drugs: An update. <i>Molecular Oncology</i> , 2012, 6, 657-682.	4.6	208
6	Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrolyl Hydroxyamides. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3344-3353.	6.4	193
7	Sirtuins and Disease: The Road Ahead. <i>Frontiers in Pharmacology</i> , 2012, 3, 4.	3.5	157
8	Study of 1,4-Dihydropyridine Structural Scaffold: Discovery of Novel Sirtuin Activators and Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5496-5504.	6.4	147
9	SIRT1 Activation by Natural Phytochemicals: An Overview. <i>Frontiers in Pharmacology</i> , 2020, 11, 1225.	3.5	146
10	Small-Molecule Inhibitors of Histone Acetyltransferase Activity: Identification and Biological Properties. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 6897-6907.	6.4	134
11	Epigenetic Multiple Ligands: Mixed Histone/Protein Methyltransferase, Acetyltransferase, and Class III Deacetylase (Sirtuin) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2279-2290.	6.4	133
12	Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype. <i>Frontiers in Pharmacology</i> , 2019, 10, 38.	3.5	128
13	Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. <i>EMBO Reports</i> , 2009, 10, 776-782.	4.5	125
14	Rexinoid-Triggered Differentiation and Tumor-Selective Apoptosis of Acute Myeloid Leukemia by Protein Kinase A-Mediated Desubordination of Retinoid X Receptor. <i>Cancer Research</i> , 2005, 65, 8754-8765.	0.9	111
15	c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2542-2555.	7.0	105
16	Rarity of Human T Helper 17 Cells Is due to Retinoic Acid Orphan Receptor-Dependent Mechanisms that Limit Their Expansion. <i>Immunity</i> , 2012, 36, 201-214.	14.3	103
17	1,3,4-Oxadiazole-Containing Histone Deacetylase Inhibitors: Anticancer Activities in Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6259-6265.	6.4	102
18	Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2788-2792.	2.2	96

#	ARTICLE	IF	CITATIONS
19	N ^ε -lysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 2795-2800.	7.1	93
20	Feijoa sellowiana derived natural Flavone exerts anti-cancer action displaying HDAC inhibitory activities. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1902-1914.	2.8	89
21	Discovery of Salermide-Related Sirtuin Inhibitors: Binding Mode Studies and Antiproliferative Effects in Cancer Cells Including Cancer Stem Cells. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10937-10947.	6.4	84
22	Development of 1,2,4-Oxadiazoles as Potent and Selective Inhibitors of the Human Deacetylase Sirtuin 2: Structure-Activity Relationship, X-ray Crystal Structure, and Anticancer Activity. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2344-2360.	6.4	82
23	UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression. <i>Oncogene</i> , 2012, 31, 5061-5072.	5.9	77
24	Antiproliferative, Antibacterial and Antifungal Activity of the Lichen <i>Xanthoria parietina</i> and Its Secondary Metabolite Parietin. <i>International Journal of Molecular Sciences</i> , 2015, 16, 7861-7875.	4.1	77
25	Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. <i>Oncogene</i> , 2010, 29, 105-116.	5.9	73
26	Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1. <i>Leukemia</i> , 2012, 26, 662-674.	7.2	72
27	Epigenetic Silencing of Peroxisome Proliferator-Activated Receptor β Is a Biomarker for Colorectal Cancer Progression and Adverse Patients' Outcome. <i>PLoS ONE</i> , 2010, 5, e14229.	2.5	69
28	Biological interactions of biocompatible and water-dispersed MoS ₂ nanosheets with bacteria and human cells. <i>Scientific Reports</i> , 2018, 8, 16386.	3.3	66
29	Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1132-1135.	2.2	63
30	1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1471-1491.	6.4	60
31	Synthesis and Biological Properties of Novel, Uracil-Containing Histone Deacetylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 6046-6056.	6.4	57
32	Evaluation of a large library of (thiazol-2-yl)hydrazones and analogues as histone acetyltransferase inhibitors: Enzyme and cellular studies. <i>European Journal of Medicinal Chemistry</i> , 2014, 80, 569-578.	5.5	54
33	HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. <i>Journal of Molecular Endocrinology</i> , 2010, 45, 219-228.	2.5	53
34	Antiviral Activity of <i>Vitis vinifera</i> Leaf Extract against SARS-CoV-2 and HSV-1. <i>Viruses</i> , 2021, 13, 1263.	3.3	53
35	Synthesis and Biological Validation of Novel Synthetic Histone/Protein Methyltransferase Inhibitors. <i>ChemMedChem</i> , 2007, 2, 987-991.	3.2	52
36	Synthesis of Benzamides Related to Anacardic Acid and Their Histone Acetyltransferase (HAT) Inhibitory Activities. <i>ChemMedChem</i> , 2008, 3, 1435-1442.	3.2	52

#	ARTICLE	IF	CITATIONS
37	Epigenetic profiling of the antitumor natural product psammaplin A and its analogues. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 3637-3649.	3.0	52
38	Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2394-2404.	4.1	49
39	Bispyridinium Dienes: Histone Deacetylase Inhibitors with Selective Activities. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 2497-2505.	6.4	48
40	HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2008, 1783, 2030-2038.	4.1	48
41	Indole-Derived Psammaplin A Analogues as Epigenetic Modulators with Multiple Inhibitory Activities. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9467-9491.	6.4	48
42	Acute myeloid leukemia: Therapeutic impact of epigenetic drugs. <i>International Journal of Biochemistry and Cell Biology</i> , 2005, 37, 1752-1762.	2.8	47
43	DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment. <i>Epigenetics</i> , 2020, 15, 439-453.	2.7	46
44	<i>Psidium guajava</i> L. anti-neoplastic effects: induction of apoptosis and cell differentiation. <i>Cell Proliferation</i> , 2012, 45, 22-31.	5.3	45
45	Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. <i>Journal of Cellular Biochemistry</i> , 2006, 98, 1163-1184.	2.6	43
46	Anticancer activities of anthocyanin extract from genotyped <i>Solanum tuberosum</i> L. "Vitelotte". <i>Journal of Functional Foods</i> , 2015, 19, 584-593.	3.4	43
47	Identification of Tri- and Tetracyclic Pyrimidinediones as Sirtuin Inhibitors. <i>ChemMedChem</i> , 2010, 5, 674-677.	3.2	40
48	RIP1-HAT1-SIRT Complex Identification and Targeting in Treatment and Prevention of Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2886-2900.	7.0	40
49	HDAC Inhibitors Repress BARD1 Isoform Expression in Acute Myeloid Leukemia Cells via Activation of miR-19a and/or b. <i>PLoS ONE</i> , 2013, 8, e83018.	2.5	40
50	Piroxicam and Cisplatin in a Mouse Model of Peritoneal Mesothelioma. <i>Clinical Cancer Research</i> , 2006, 12, 6133-6143.	7.0	39
51	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 127-138.	5.5	39
52	Histone deacetylase inhibitors: a patent review (2009 - 2011). <i>Expert Opinion on Therapeutic Patents</i> , 2013, 23, 1-17.	5.0	37
53	Identification and characterization of PKF118-310 as a KDM4A inhibitor. <i>Epigenetics</i> , 2017, 12, 198-205.	2.7	36
54	Natural compounds in epigenetics: A current view. <i>Food and Chemical Toxicology</i> , 2014, 73, 71-83.	3.6	35

#	ARTICLE	IF	CITATIONS
55	Inhibition of Histone Demethylases LSD1 and UTX Regulates ER α Signaling in Breast Cancer. <i>Cancers</i> , 2019, 11, 2027.	3.7	34
56	Context-Selective Death of Acute Myeloid Leukemia Cells Triggered by the Novel Hybrid Retinoid-HDAC Inhibitor MC2392. <i>Cancer Research</i> , 2014, 74, 2328-2339.	0.9	33
57	The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia. <i>Oncogene</i> , 2018, 37, 2559-2572.	5.9	32
58	Discovery of the First-in-Class GSK-3 β /HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 469-474.	2.8	32
59	“Stockpile” of Slight Transcriptomic Changes Determines the Indirect Genotoxicity of Low-Dose BPA in Thyroid Cells. <i>PLoS ONE</i> , 2016, 11, e0151618.	2.5	32
60	Growth Factor-Antagonized Retinoid Apoptosis Involves Permissive PPAR γ /RXR Heterodimers to Activate the Intrinsic Death Pathway by NO. <i>Cancer Cell</i> , 2009, 16, 220-231.	16.8	31
61	BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition. <i>Cell Death and Disease</i> , 2019, 10, 338.	6.3	31
62	Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents. <i>European Journal of Medicinal Chemistry</i> , 2019, 162, 290-320.	5.5	31
63	Identification of Two New Synthetic Histone Deacetylase Inhibitors That Modulate Globin Gene Expression in Erythroid Cells from Healthy Donors and Patients with Thalassemia. <i>Molecular Pharmacology</i> , 2007, 72, 1111-1123.	2.3	30
64	Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: Coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 3659-3668.	3.0	30
65	Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells. <i>Clinical Epigenetics</i> , 2019, 11, 68.	4.1	30
66	ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias. <i>Epigenetics</i> , 2015, 10, 6-18.	2.7	29
67	Comparative Phytochemical Characterization, Genetic Profile, and Antiproliferative Activity of Polyphenol-Rich Extracts from Pigmented Tubers of Different <i>Solanum tuberosum</i> Varieties. <i>Molecules</i> , 2020, 25, 233.	3.8	29
68	Histone Deacetylase Inhibitors: Recent Insights from Basic to Clinical Knowledge & Patenting of Anti-Cancer Actions. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2011, 6, 131-145.	1.6	28
69	Molecular analysis of the apoptotic effects of BPA in acute myeloid leukemia cells. <i>Journal of Translational Medicine</i> , 2009, 7, 48.	4.4	27
70	HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape. <i>Oncotarget</i> , 2015, 6, 886-901.	1.8	27
71	The Role of Necroptosis: Biological Relevance and Its Involvement in Cancer. <i>Cancers</i> , 2021, 13, 684.	3.7	27
72	New pyrrole-based histone deacetylase inhibitors: Binding mode, enzyme- and cell-based investigations. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 235-247.	2.8	24

#	ARTICLE	IF	CITATIONS
73	TNF-related apoptosis-inducing ligand: Signalling of a "smart" molecule. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 460-466.	2.8	23
74	Identification of NuRSERY, a new functional HDAC complex composed by HDAC5, GATA1, EKLf and pERK present in human erythroid cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 50, 112-122.	2.8	23
75	Two novel SIRT1 activators, SCIC2 and SCIC2.1, enhance SIRT1-mediated effects in stress response and senescence. <i>Epigenetics</i> , 2020, 15, 664-683.	2.7	23
76	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: Histone deacetylase inhibition and in-cell activities. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2530-2535.	2.2	22
77	<i>Genista sessilifolia</i> DC . extracts induce apoptosis across a range of cancer cell lines. <i>Cell Proliferation</i> , 2013, 46, 183-192.	5.3	22
78	Nonlinear protein - nucleic acid crosslinking induced by femtosecond UV laser pulses in living cells. <i>Laser Physics Letters</i> , 2012, 9, 234-239.	1.4	21
79	Recent insights into Histone Acetyltransferase-1: biological function and involvement in pathogenesis. <i>Epigenetics</i> , 2021, 16, 838-850.	2.7	21
80	Histone deacetylase inhibitors: clinical implications for hematological malignancies. <i>Clinical Epigenetics</i> , 2010, 1, 25-44.	4.1	20
81	Effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability. <i>Journal of Translational Medicine</i> , 2008, 6, 27.	4.4	18
82	Gene Transactivation and Transrepression in MYC-Driven Cancers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3458.	4.1	18
83	Novel Cinnamyl Hydroxyamides and 2-Aminoanilides as Histone Deacetylase Inhibitors: Apoptotic Induction and Cytodifferentiation Activity. <i>ChemMedChem</i> , 2011, 6, 698-712.	3.2	17
84	KDM4 Involvement in Breast Cancer and Possible Therapeutic Approaches. <i>Frontiers in Oncology</i> , 2021, 11, 750315.	2.8	17
85	Design, Synthesis, and Biological Evaluation of 2-Aminobenzanilide Derivatives as Potent and Selective HDAC Inhibitors. <i>ChemMedChem</i> , 2012, 7, 1256-1266.	3.2	16
86	Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring. <i>European Journal of Medicinal Chemistry</i> , 2013, 66, 56-68.	5.5	16
87	Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1187-1202.	3.4	16
88	Enzymatic and Biological Characterization of Novel Sirtuin Modulators against Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5654.	4.1	16
89	The KDM Inhibitor GSKJ4 Triggers CREB Downregulation via a Protein Kinase A and Proteasome-Dependent Mechanism in Human Acute Myeloid Leukemia Cells. <i>Frontiers in Oncology</i> , 2020, 10, 799.	2.8	15
90	Histone deacetylase inhibitors and hemoglobin F induction in β^0 -thalassemia. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 2341-2347.	2.8	14

#	ARTICLE	IF	CITATIONS
91	The new low-toxic histone deacetylase inhibitor <i>Sirtinone</i> induces apoptosis in various acute myeloid leukaemia cells. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1758-1765.	3.6	14
92	3-Chloro-N-(2-(2-hydroxybenzylidene) benzohydrazide): An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy. <i>Frontiers in Pharmacology</i> , 2018, 9, 1006.	3.5	14
93	SIRT1 pharmacological activation rescues vascular dysfunction and prevents thrombosis in MTHFR deficiency. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	5.4	14
94	TRAIL: At the Center of Drugable Anti-Tumor Pathways. <i>Cell Cycle</i> , 2005, 4, 914-918.	2.6	13
95	Novel pyrrole-containing histone deacetylase inhibitors endowed with cytodifferentiation activity. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1510-1522.	2.8	13
96	Novel Antiproliferative Chimeric Compounds with Marked Histone Deacetylase Inhibitory Activity. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 973-978.	2.8	13
97	Designing Dual Transglutaminase/2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death. <i>ChemMedChem</i> , 2018, 13, 227-230.	3.2	13
98	Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia. <i>Oncotarget</i> , 2018, 9, 25647-25660.	1.8	13
99	Forskolin Sensitizes Human Acute Myeloid Leukemia Cells to H3K27me2/3 Demethylases GSKJ4 Inhibitor via Protein Kinase A. <i>Frontiers in Pharmacology</i> , 2018, 9, 792.	3.5	13
100	Synthesis and Biological Evaluation of Tripartin, a Putative KDM4 Natural Product Inhibitor, and Dichloromethylindenol Analogues. <i>ChemMedChem</i> , 2018, 13, 1949-1956.	3.2	13
101	Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6284-6288.	2.2	12
102	Oxidative nucleophilic substitution selectively produces cambinol derivatives with antiproliferative activity on bladder cancer cell lines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 78-82.	2.2	12
103	Trifolium Repens Blocks Proliferation in Chronic Myelogenous Leukemia via the BCR-ABL/STAT5 Pathway. <i>Cells</i> , 2020, 9, 379.	4.1	12
104	Marine-Derived Secondary Metabolites as Promising Epigenetic Bio-Compounds for Anticancer Therapy. <i>Marine Drugs</i> , 2021, 19, 15.	4.6	12
105	Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 7992-8002.	3.0	11
106	Time-resolved analysis of DNA-protein interactions in living cells by UV laser pulses. <i>Scientific Reports</i> , 2017, 7, 11725.	3.3	11
107	Pyrrole-Based Hydroxamates and Aminoanilides: Histone Deacetylase Inhibition and Cellular Activities. <i>ChemMedChem</i> , 2009, 4, 1411-1415.	3.2	9
108	The Pan-Sirtuin Inhibitor MC2494 Regulates Mitochondrial Function in a Leukemia Cell Line. <i>Frontiers in Oncology</i> , 2020, 10, 820.	2.8	8

#	ARTICLE	IF	CITATIONS
109	Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation. <i>Cancers</i> , 2020, 12, 447.	3.7	8
110	Novel Pyridine-Based Hydroxamates and 2-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity. <i>ChemMedChem</i> , 2021, 16, 989-999.	3.2	8
111	Developing novel non-hydroxamate histone deacetylase inhibitors: the chelidamic warhead. <i>MedChemComm</i> , 2012, 3, 298-304.	3.4	7
112	Combined HAT/EZH2 modulation leads to cancer-selective cell death. <i>Oncotarget</i> , 2018, 9, 25630-25646.	1.8	5
113	Relevance of AIF/CypA Lethal Pathway in SH-SY5Y Cells Treated with Staurosporine. <i>International Journal of Molecular Sciences</i> , 2022, 23, 265.	4.1	5
114	Analysis of Chromatin-Nuclear Receptor Interactions by Laser-Chromatin Immunoprecipitation. <i>Methods in Molecular Biology</i> , 2014, 1204, 25-34.	0.9	2
115	Different Approaches to Unveil Biomolecule Configurations and Their Mutual Interactions. <i>Analytical Letters</i> , 2021, 54, 40-56.	1.8	1
116	Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. <i>EMBO Reports</i> , 2020, 21, e51028.	4.5	1